AgenciesLupin Ltd
Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator for its generic version of Prucalopride tablets indicated for treatment of chronic idiopathic constipation. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application of Prucalopride tablets of strengths 1 mg and 2 mg, Lupin Ltd said in a regulatory filing. These are bioequivalent to Motegrity Tablets, 1 mg and 2 mg of Takeda Pharmaceuticals USA. Inc, it added. “This product will be manufactured at Lupin’s Goa facility in India,” the company said. Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation (CIC) in adults.Live Events Citing IQVIA MAT April 2025 data, the company said Prucalopride tablets 1 mg and 2 mg had estimated annual sales of USD 184 million in the US.(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onlupin ltdLupin USFDA approvalPrucalopride tabletschronic idiopathic constipation treatmentUSFDA drug approval newsgeneric chronic constipation drugPrucalopride 1 mg 2 mgpharmausfdatakeda pharmaceuticals usa
(Catch all the Business News, Breaking News, Budget 2025 Events and Latest News Updates on The Economic Times.) Subscribe to The Economic Times Prime and read the ET ePaper online….moreless
(You can now subscribe to our Economic Times WhatsApp channel)Read More News onlupin ltdLupin USFDA approvalPrucalopride tabletschronic idiopathic constipation treatmentUSFDA drug approval newsgeneric chronic constipation drugPrucalopride 1 mg 2 mgpharmausfdatakeda pharmaceuticals usa(Catch all the Business News, Breaking News, Budget 2025 Events and Latest News Updates on The Economic Times.) Subscribe to The Economic Times Prime and read the ET ePaper online….moreless